Trial Profile
Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Amlodipine/rosuvastatin/telmisartan (Primary) ; Amlodipine/telmisartan; Rosuvastatin
- Indications Dyslipidaemias; Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Daewon Pharmaceutical
- 30 Jan 2018 Status changed from active, no longer recruiting to completed.
- 12 Jul 2017 New trial record